Chronic Obstructive Pulmonary Disease Copd — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic obstructive pulmonary disease copd . 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
5
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators in Chronic Obstructive Pulmonary Disease Copd

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Verona Pharma 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic obstructive pulmonary disease copd . Each bar = one year. Y-axis scaled to peak year (2 patents).

1
31
2
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Ohtuvayre
ENSIFENTRINE
 Verona Pharma 5 64 — 2031-08-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9062047 Ohtuvayre method of use 81 2031-08-21
9956171 Ohtuvayre method of use 75 2035-09-15
10945950 Ohtuvayre formulation 55 2035-09-15
12409180 Ohtuvayre formulation 55 2043-02-20
12251384 Ohtuvayre formulation 55 2044-06-25

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12251384 Ohtuvayre formulation 55 2044-06-25
12409180 Ohtuvayre formulation 55 2043-02-20
10945950 Ohtuvayre formulation 55 2035-09-15
9956171 Ohtuvayre method of use 75 2035-09-15
9062047 Ohtuvayre method of use 81 2031-08-21

Related